Application of Molecular Genetics for Diagnosing Familial Hypercholesterolemia in Norway: Results from a Family-Based Screening Program

A total of 119 different mutations in the low-density lipoprotein-receptor gene have so far been found to cause familial hypercholesterolemia (FH) among Norwegian patients. As of April 2003, 2390 patients from 959 unrelated families were provided with a molecular genetic diagnosis. Of these, 25.3% had xanthomas and 8.4% had xanthelasma. During the last 2-3 years, a systematic family-based program to identify close relatives of FH patients has been established. A total of 851 relatives of 188 index patients have undergone genetic testing. Four hundred seven people (47.9%) were affected, and 444 (52.1%) were unaffected. Only 41.5% of those affected were on lipid-lowering drugs, and only 6.1% had a value for total serum cholesterol below 193 mg/dL (5.0 mmol/L). A follow-up study was conducted in 146 of 407 affected relatives 6 months after genetic testing was performed. Of those already under treatment at the time of genetic testing, nonsignificant reductions of total serum cholesterol and low-density lipoprotein cholesterol of 3.2% and 7.1% were observed. Of those not under treatment who were aged 18 years and older, the corresponding reductions were 21.2% (p < .0001) and 30.0% (p < .0001), respectively. We conclude that molecular genetic methods represent a feasible and highly efficient tool in a family-based strategy to diagnose FH.

familial hypercholesterolemia - genetics - low-density lipoprotein-receptor - mutation

REFERENCES

• 1 Goldstein J L, Hobbs H H, Brown M S. Familial hypercholesterolemia. In: Scriver CR, Baudet AL, Sly WS, Valle D The Metabolic Basis of Inherited Disease. New York; McGraw-Hill 2001: 2863-2913
• 2 Slack J. Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states.  Lancet. 1969;  2 1380-1382
• 3 Williams R R, Hamilton-Craig I, Kostner G M et al.. MED PED: an integrated genetic strategy for preventing early deaths. In: Berg K, Boulyjenkov V, Christen Y Genetic Approaches to Noncommunicable Diseases. Berlin; Springer 1996: 35-46
• 4 Umans-Eckenhausen M AW, Defesche J C, Sijbrands E JG et al.. Review of the first 5 years of screening for familial hypercholesterolemia in the Netherlands.  Lancet. 2001;  357 165-168
• 5 Wood D, De Backer G, Faergeman O et al.. Prevention of coronary heart disease in clinical practice: recommendation of the second task force of European and other societies on coronary prevention.  Atherosclerosis. 1998;  140 199-270
• 6 Leren T P, Tonstad S, Rødningen O K et al.. Molecular genetics of familial hypercholesterolemia in Norway.  J Intern Med. 1997;  241 185-194
• 7 Heiberg A, Berg K. The inheritance of hyperlipoproteinemia with xanthomatosis. A study of 132 kindreds.  Clin Genet. 1976;  9 203-233
• 8 Fouchier S W, Defesche J C, Umans-Eckenhausen M W, Kastelein J P. The molecular basis of familial hypercholesterolemia in the Netherlands.  Hum Genet. 2001;  109 602-615
• 9 Soria L F, Ludwig E H, Clarke H RG, Vega G L, Grundy S M, McCarthy B J. Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100.  Proc Natl Acad Sci USA. 1989;  86 587-591
• 10 Eiken H G, Odland E, Boman H et al.. Application of natural and amplification created restriction sites for the diagnosis of PKU mutations.  Nucleic Acids Res. 1991;  19 1427-1430
• 11 Friedewald W T, Levy R I, Fredrickson D S. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge.  Clin Chem. 1972;  18 499-502
• 12 Umans-Eckenhausen M AW, Sijbrands E JG, Kastelein J JP et al.. Low-density lipoprotein receptor gene mutations and cardiovascular risk in a large genetic cascade screening population.  Circulation. 2002;  106 3031-3036
• 13 Umans-Eckenhausen M AW, Defesche J C, van Dam M J et al.. Long-term compliance with lipid-lowering medication after genetic screening for familial hypercholesterolemia.  Arch Intern Med. 2003;  163 65-68